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ABSTRACT
Background: Epistaxis is an important emergency that can sometimes be life
hreatening without effective intervention. Persistent and recurrent bleeding can lead
o aspiration, hypotension, hypoxia, or even severe and mortal cardiovascular com-
lications. Providing prompt hemostasis is important, and the hemostatic method
sed must be easily and locally applicable, efficient, and inexpensive.
Objective: The aim of this study was to assess the hemostatic efficacy of
Ankaferd Blood Stopper (ABS) in an experimental epistaxis model and to determine
the histopathologic alterations with topical ABS application.
Methods: Twenty-eight New Zealand rabbits were evaluated in 4 study
groups. Topical ABS, gelatin foam (GF), adrenalin  lidocaine (AL), and serum
physiologic as negative control (C) were applied to the animals for controlling
epistaxis. The bleeding was generated with a standard mucosal incision in all groups.
Cotton pieces soaked with ABS, AL, C, and GF were applied to the nasal bleeding
area. Time of hemostasis was recorded. Tissue samples were obtained after hemostasis
for histopathologic examination. The samples were stained with hematoxylin and
eosin (HE) and phosphotungstic acid hematoxylin (PTAH) and were examined under
a light microscope. In this experimental study, the observers were blind to ABS, AL,
and C but not to GF, because of its solid nature.
Results: Median durations required for hemostasis in ABS, AL, GF, and C
groups were recorded as 30, 90, 90, and 210 seconds, respectively. The time until
termination of bleeding in the ABS group was significantly shorter than that in the
AL, GF, and C groups (P  0.002, P  0.002, and P  0.001, respectively). On
istopathologic evaluation, after staining with HE, minimal fibrin at the incision
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Current Therapeutic Researchedges and a few extravasated erythrocytes were observed in the C, AL, and GF groups.
In the ABS group, a dark amorphous material surrounded by fibrin, filling the space
between the edges of incisions, was noticed. Fibrin was determined in the C, GF, and
AL groups with PTAH stain and in the positive control group. In the ABS group, it
was observed that the amorphous substance surrounded by fibrin seen in the HE
sections was not stained with PTAH.
Conclusions: Topical nasal ABS application controlled epistaxis faster than
C, GF, and AL in this animal bleeding model. The bleeding model used here might
fail to replicate the type of injury that would be likely to result in life-threatening
bleeding in humans, which should be considered a limitation of the present study.
The histopathologic findings in the nasal incision area suggest that ABS might affect
global hemostasis by inducing a unique protein network formation, potentially
representing a different mechanism of action among conventional antihemorrhagic
applications. (Curr Ther Res Clin Exp. 2011;72:185–194)
2011 Elsevier HS Journals, Inc.
Key words: Ankaferd Blood Stopper, epinephrine, epistaxis, gelatin foam,
idocaine, rabbit.
INTRODUCTION
Epistaxis, bleeding from the nose, is an important emergency that may rarely be life
threatening without effective intervention. Almost every physician has encountered
epistaxis at least once in the outpatient clinic or emergency unit.1 Approximately
60% of the population have nosebleeds at least once in their lifespan, and some of
them require medical intervention.2 However, in a minority of the patients, persistent
nd recurrent bleeding may lead to aspiration, hypotension, hypoxia, and even severe
nd mortal cardiovascular complications (eg, myocardial infarction).3 Several methods
or techniques have been described to control epistaxis. Therapeutic methods can be
classified under 2 headings: medical and surgical. Medical options to stop bleeding
include cauterization with electrocautery or silver nitrate, gauze pad, absorbable
hemostatic sponges, cotton impregnated with vasoconstrictor agents, and balloon
methods. Surgical interventions include embolization, cryosurgery, septoplasty, and
arterial ligation. The aim of all these therapeutic methods is to cease bleeding and
diminish the rate of complications and treatment cost. Providing prompt hemostasis
is important for patient comfort, length of hospital stay, prevention of complications,
and cost of treatment. The hemostatic method being used must be easily and locally
applicable, easily available, highly efficient, and inexpensive. Elucidation of the
Ankaferd Blood Stopper (ABS; Ankaferd Medical Products Inc, Istanbul, Turkey) as
a topical hemostatic agent in the setting of epistaxis is important for better clinical
management of this challenging surgical emergency.
ABS is a novel topical hemostatic agent, which is indicated in surgical procedures
when conventional control of bleeding by ligature or conventional procedure is
ineffective. The mechanism of hemostatic effect of ABS is the formation of an
Open access under the Elsevier OA license.encapsulated protein network representing focal points for vital erythrocyte aggre-
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M. Kelles et al.gation. The use of ABS in experimental studies,4,5 gastrointestinal bleedings,6–11
urologic surgery,5,12 tonsillectomy,13 and acute anterior epistaxis14 have been re-
orted in the literature. According to these studies, ABS seems to be effective as a
opical hemostatic agent.
In some conditions, it may take extensive time to control bleeding with known
emostatic agents. There are some reported cases in published literature about this
ituation and the results after ABS application.8,9 Despite these reports, there is no
research in the literature comparing hemostatic efficacy and bleeding control time of
ABS with other known hemostatic agents. Comparative histopathologic findings may
help elucidate the hemostatic activity of this new agent. The aim of this study was
to assess the hemostatic efficacy of ABS in an experimental epistaxis model and to
determine the histopathologic alterations associated with topical ABS application.
METHODS
This study included 28 male, white, 20- to 42-week old (mean, 31 weeks) New
Zealand rabbits weighing between 3000 and 5000 g (mean, 3850 g). They were fed
rabbit growing pellets obtained from Korkutelim Feed Company (Antalya, Turkey)
and fresh tap water. Room light was adjusted to 12-hour periods of dark and light;
room temperature was set at 22°C (1°C), and humidity was set at 45%. The rabbits
were divided into 4 groups: the ABS group, the gelatin foam (GF) group (GELITA-
SPON, Gelita Medical, Amsterdam, the Netherlands), the 0.0125 mg/mL adrenaline
plus 20 mg/mL lidocaine (AL) group (Jetokain Ampul, Adeka Inc, Samsun, Turkey),
and the serum physiologic group as negative control (C), each consisting of 7 rabbits.
Because AL and GF are commonly used hemostatic agents, they were used as the other
treatment groups.
Surgical Procedure
In all groups, 80 mg/kg of ketamine hydrochloride (Alfamine 10%; Alfasan Inc,
oerden, Netherlands) and 2 mg/kg of xylazine hydrochloride (Alfazyne 2%; Alfasan
nc) were intramuscularly administered as anesthesia. Each rabbit was given anesthe-
ia only once under the same conditions. After administration of anesthetic agent, a
ucosal incision using a blade, approximately 1 cm in length, was made on the
nterior part of the septum in the right nasal passage of each rabbit to achieve
leeding.
Interventions
ABS, AL, and C were put into injectors covered with black bands, each numbered
andomly. Because of GF’s lack of fluid, study of the GF group could not be blinded.
hen, 1  1 cm cotton pieces with 0.5 mL of ABS, AL, or C and 1  1 cm of GF
ere applied to the bleeding area. During these double-blind processes, the investi-
ators who performed the experiments and collected data were unaware of the agent
sed in the cotton, except for GF because of its solid nature. The bleeding area was
nspected by removing the material every 30 seconds until bleeding stopped. Intervals
or termination of bleeding were recorded.
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Current Therapeutic ResearchHistopathologic Examinations
For the evaluation of histopathologic changes in the incision area, biopsy speci-
ens of 0.5 cm, including the incision site, were collected 10 minutes after the
ermination of bleeding. The specimens were fixed in standard 10% formaldehyde
olution and kept for histopathologic examination. During pathologic examination, 2
ections in 5-m thickness were cut. One of them was stained with hematoxylin and
eosin (HE) and the other was stained with phosphotungstic acid hematoxylin
(PTAH). They were both examined under a light microscope. The investigator who
performed the pathologic examinations of specimens was unaware of which specimen
received which agent.
Statistical Analyses
SPSS for Windows 13 software (SPSS Inc, Chicago, Illinois) was used for statistical
nalysis. Measurable variables were presented as median with ranges (minimum and
aximum values). As a result of the Shapiro-Wilk normality test, the measurable
ariables were not normally distributed (P  0.05). Therefore, Kruskal-Wallis
ariance analysis was used for the comparison of all groups and Mann-Whitney U test
ith Bonferroni test was used to compare paired groups. A P value  0.05 was
ccepted as statistically significant.
Inonu University Ethics Committee for Experimental Animals (Research Protocol
o: 2009-12) gave approval for the performance of the study.
RESULTS
In this experimental epistaxis model on rabbits, the time intervals for termination of
bleeding were measured as 30 (range, 30–60), 90 (range, 60–150), 90 (range,
60–180), and 210 seconds (range, 180–300) in the rabbits that received cotton pieces
soaked with ABS, AL, GF, and C, respectively. The period for termination of bleeding
in the ABS group was significantly shorter than the AL (P 0.002), GF (P 0.002),
nd C (P  0.001) groups. When compared separately, the periods for termination
f bleeding in the AL and GF groups were significantly shorter than that of the C
roup (P  0.002). There was no significant difference found between the periods for
ermination of bleeding in the AL and GF groups (P  0.789).
On histopathologic evaluation, stained with HE, similar histomorphologic pat-
erns were observed at incision edges in the groups that received C, AL, and GF.
inimal fibrin at incision edges and a few extravasated erythrocytes were observed
Figure 1). In the ABS group, a dark amorphous material surrounded by fibrin, filling
he space between the edges of the incisions, was seen (Figure 2).
PTAH staining was applied to identify whether the fibrin-like amorphous sub-
tance at the incision line of all groups was fibrin. Sections prepared from fibrin
ithout stain were used as positive controls. Fibrin was determined in the C, GF, and
L groups with PTAH stain and in the positive control group (Figure 3). In the ABS
roup, ABS formed a protein network; it was observed that the amorphous substance
urrounded by fibrin seen on the HE sections was not stained with PTAH (Figure 4).
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Epistaxis may be an extremely difficult situation and potentially life threatening
because of major bleeding.15 To control nosebleeding, various medical or surgical
therapeutic protocols are implemented based on the type, severity, and cause of
bleeding.16 Some of the medical methods used to control bleeding include cotton
mpregnated with AL or GF.3
Although there are articles mentioning the use of AL-absorbed cotton ribbons for
ocal anesthesia and vasoconstriction in epistaxis,3 no study comparing locally applied
AL soaked into cotton with other agents was found in the literature. The comparative
Figure 1. Minimal fibrin at incision edges in adrenalin  lidocaine, gelatin foam, and
negative control groups (arrow) (hematoxylin and eosin  400).
Figure 2. Dark amorphous substance (arrow) surrounded by fibrin at incision line (arrow-
head) in ABS group (hematoxylin and eosin  400).
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Current Therapeutic Researchstudies about AL are related to its local injection. It was reported that 1% lidocaine 
1:100000 adrenalin was injected for vasoconstriction in persistent nosebleeding.15
Wormald et al17 reported that bleeding decreased by injection of lidocaine 2% 
drenalin 1:80.000 in endoscopic sinus surgery. Çiftçi et al18 reported results of
atients who underwent dacryocystorhinostomy with general or local anesthesia. They
bserved epistaxis in 12 of the 182 patients under general anesthesia and 2 of 298
atients under local anesthesia with implementation of 2% of lidocaine  1:100000
drenalin combination. They also reported some adverse effects of adrenalin, includ-
ng tachycardia, arrhythmia, and hypertension in the local anesthesia group.
GF is an absorbable hemostatic agent produced from the gelatin in animal skin.19
It adheres to the bleeding site, activates platelets, and triggers aggregation.20 Ross-
Figure 3. Fibrin at incision lines in adrenalin  lidocaine, gelatin foam, and negative
control groups (arrow) (phosphotungstic acid hematoxylin  400).
Figure 4. Amorphous substance (arrow) surrounded by fibrin (arrowhead) in Ankaferd
Blood Stopper group (phosphotungstic acid hematoxylin  400).
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M. Kelles et al.mann et al21 applied pressure to wound sites with oxidized cellulose, GF, and gauze
pads to control bleeding in 30 patients. They reported that duration of hemostasis was
considerably shorter in the groups that received GF and oxidized cellulose compared
with the control group. However, they reported that bleeding recurred in 40% of the
groups of oxidized cellulose and controls, whereas bleeding did not recur in the GF
group.21 Petersen et al22 reported that they placed oxidized regenerated cellulose and
GF into the alveolus of extracted teeth, without any difference between 2 groups in
terms of bleeding.
ABS-induced formation of a protein network with vital erythroid aggregation
covers the entire physiologic hemostatic process.23–25 Mainly, there are distinct
important components of the ABS-induced hemostatic network. Vital erythroid
aggregation takes place with the spectrin and ankrin receptors on the surface of red
blood cells. Those proteins and the required adenosine triphosphate bioenergy are
included in the ABS protein library. ABS also upregulates the GATA/FOG tran-
scription system affecting erythroid functions. Urotensin II is also an essential
component of ABS and represents the link between injured vascular endothelium,
adhesive proteins, and active erythroid cells.23,25,26 These concepts have been devel-
oped via Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometer
(MALDI-TOF) proteomic molecular analyses, cytometric arrays, transcription analy-
sis, and SEM ultrastructural examinations as well as numerous investigations inter-
acting with in vitro and in vivo research settings.23,25,26 Three clinical ABS Phase III
tudies in humans performed in vascular port insertion bleedings, anterior epistaxis,
nd post-tonsillectomy hemorrhages proved its use as a hemostatic agent.13,14,27
Therefore, ABS could effectively be used both in individuals with normal hemostatic
parameters and in patients with deficient primary hemostasis and/or secondary
hemostasis. In vitro data on the antibacterial and wound healing profile of ABS as well
as a bleeding control in human gastrointestinal disorders8–10 and human mediastinal
leedings27 sheds further light on these critical issues.
Al et al27 investigated the efficacy of ABS to control cutaneous and subcutaneous
hemorrhages that resulted from vascular access in 69 patients with malignancy. This
study compared the duration of hemostasis in 37 patients who received an ABS-
absorbed tampon at the bleeding sites with 32 patients who received a dry gauze
tampon. They reported the mean termination time of bleeding as 32.97 (29.9)
seconds in the ABS group and 123.75 (47.5) seconds in the second group. They
reported that bleeding recurred 24% and 50%, respectively. Teker et al13 evaluated
7 patients who underwent cryogenic tonsillectomy, who received ABS for hemor-
haging at the right tonsillar bed; suture ligation technique was used at the left side.
hey reported that hemostasis duration was significantly lower in the ABS site than
n the sutured site. ABS was also successful in stopping gastrointestinal and nose-
leeding in a case in which conventional methods did not work.9 These findings,
obtained from human studies, represented the initial clues for clinical approval of
ABS as a hemostatic agent in Turkey.
In rabbits, physiologic mean blood clotting time is 210 seconds (range, 60–
360).28 In the present study, hemorrhage stopped in the ABS, AL, GF, and C groups
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180–300) seconds, respectively. These results showed that ABS was more effective for
bleeding control than GF and AL. These findings, obtained from experimental
studies, will be used in novel trials intended to compare the tolerability and efficacy
of ABS among other hemostatic agents in the future.
The groups that received C, AL, and GF showed similar histomorphologic features
at the incision edges when stained with HE (Figure). On these materials, there were
minimal fibrin and a few extravasated erythrocytes at the incision sites. In the ABS
group, an acellular, dark eosinophilic, amorphous material surrounded with fibrin
filling the gap between the incision edges was seen (Figure 2). The dark amorphous
material seen in the ABS group was unique compared with the other groups because
it was related to the unique ABS-induced hemostatic network. Protein agglutination
with numerous red blood cells comprised the dark amorphous material observed in
the ABS group. This finding requires further clinicopathologic correlations regarding
the efficacy and hemostatic mechanism of ABS.
PTAH is used to recognize fibrin, glial fibrils, and muscle tissue. Fibrin tissue is
seen as fibrils, in blue, with PTAH.29 In this study, the slides were dyed with PTAH
tain to identify whether the fibrin-like amorphous substance seen at the incision sites
f all the groups was fibrin. The presence of fibrin was determined in the C, AL, and
F groups with PTAH staining (Figure 3). In the ABS group, the amorphous
ubstance seen in HE sections was not dyed with PTAH (Figure 4). These findings
upported Goker et al’s hypotheses,30 which indicated that ABS stops bleeding
hrough protein network formation and erythrocyte aggregation.
CONCLUSIONS
ABS was found to be more effective than AL and GF as an epistaxis treatment. In our
study, ABS decreased bleeding duration from 210 (range, 180–300) to 30 (range,
30–60) seconds. According to the histopathologic findings, ABS might stop bleeding
by means of protein network formation. This agent has the potential to be used in
many hemorrhagic cases. In serious cases of epistaxis, there are underlying structural
and/or hematologic pathologies that predispose patients to severe nasal bleeding. In
these cases, management can be considered a potential emergency. However, it is not
clear whether the bleeding model used here replicates the type of injury that would
be likely to result in life-threatening bleeding in humans. This was a significant issue
that affected the interpretation of these results and should be considered as a
limitation of the present study. Further investigations are needed to elucidate the
place of ABS hemostatic effects on distinct tissues in various in vivo trauma models,
including the model of bleeding diathesis.
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